Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Soleno Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Soleno Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Soleno Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Soleno Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Soleno Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Soleno Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Soleno Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Soleno Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Soleno Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Soleno Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Anish Bhatnagar, M.D. has been the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 2014, President since December 31, 2013. Dr. Bhatnagar has been Director at Soleno Therapeutics, Inc. since February 02, 2014. Dr. Bhatnagar served as the Chief Operating Officer of Capnia, Inc. and served as its Chief Medical Officer of Clinical & Regulatory. He served as Senior Vice President of Clinical & Regulatory of Capnia Inc. He is a physician with over 15 years of clinical and regulatory experience in the biopharmaceutical and medical device industry. His experience spans development of biologics, drugs, drug-device combinations and medical devices. He has extensive experience in the pharmaceutical industry in all aspects of drug and device development from pre-IND to Phase III and Expanded Access as well as BLA submission. He has implemented clinical trials in neurology, psychiatry, pulmonary/allergy, cardiovascular disease, endocrine/metabolic disease and hematology/oncology in North America, South America, Asia, Africa as well as Western and Eastern Europe. He has been the lead in regulatory interactions with several divisions at the FDA and international regulatory authorities (such as those in the UK, France, Australia and Sweden). He joined Capnia, Inc. since 2006. His experience includes working at Coulter Pharmaceuticals, Inc. 1998 to 2000 and Titan Pharmaceuticals from 2000 to 2006 at increasing levels of responsibility. He is the author of several peer-reviewed publications, abstracts and book chapters. He completed his Residency and Fellowship training at Georgetown University Hospital and the University of Pennsylvania. He obtained his medical degree at SMS Medical College in Jaipur, India.
Anish's compensation has increased whilst company is loss making.
Anish's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Soleno Therapeutics management team is about average.
Senior Vice President of Research & Development
CFO & Principal Accounting Officer
Senior Vice President of Drug Development
Head of Regulatory Affairs and Quality
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Soleno Therapeutics board of directors is about average.
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.